• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Data Knights Acquisition Corp.

    10/17/23 9:29:17 AM ET
    $DKDCA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $DKDCA alert in real time by email
    425 1 tm2328586d1_8k.htm 425

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 13, 2023

     

    DATA KNIGHTS ACQUISITION CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-40386   86-2076743
    (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    Unit G6, Frome Business Park, Manor Road

    Frome

    United Kingdom, BA11 4FN

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code +44 203 833 4000

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading
    Symbol(s)
      Name of Each Exchange on Which Registered
    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant   DKDCU   The Nasdaq Stock Market LLC
    Class A Common Stock, $0.0001 par value per share   DKDCA   The Nasdaq Stock Market LLC
    Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   DKDCW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 8.01. Other Events.

     

    Revision to Proxy Card

     

    On October 2, 2023, Data Knights Acquisition Corp., a Delaware corporation (the “Company”), caused to be delivered to the shareholders of the Company (the “Shareholders”) a proxy card (the “Proxy Card”) in connection with the special meeting of the Shareholders scheduled for October 17, 2023 (the “Special Meeting”) to approve certain actions related the Company’s previously announced proposed transaction with OneMedNet Corporation, a Delaware corporation (the “Proposed Transaction”), pursuant to the Company’s Registration Statement on Form S-4 (the “Proxy Statement”) filed with the Securities and Exchange Commission the (“SEC”) on September 21, 2023 and declared effective on September 22, 2023. This Current Report on Form 8-K is filed to resolve scriveners’ errors with regards to Proposal 4 – Director Election Proposal of the Proxy Card to reflect the Proposal as correctly stated on the Proxy Statement. The Class III director nominees are Dr. Jeffrey Yu and R. Scott Holbrook. Dr. Christoph Zindel is not a director nominee.

     

    In connection with the Special Meeting, Shareholders were issued a recommendation using the Proxy Statement as the prevailing document.

     

    Additional Information and Where to Find It

     

    This Current Report on Form 8-K is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the Proxy Statement. All proposals are described in detail in the Proxy Statement.

     

    No Offer or Solicitation

     

    This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proxy Statement and shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom.

     

    Participants in Solicitation

     

    The Company and its directors and executive officers may be deemed participants in the solicitation of proxies from Shareholders in connection with the Proposed Transaction. Shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Company in Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 31, 2023. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Shareholders in connection with the Proxy Statement are set forth in the Proxy Statement. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Proposed Transaction are included in the Proxy Statement.

     

    104   Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    DATA KNIGHTS ACQUISITION CORP.

         
    Date: October 17, 2023 By:  /s/ Barry Anderson
        Barry Anderson
        Chief Executive Officer

     

     

     

    Get the next $DKDCA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DKDCA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DKDCA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)

      SC 13G/A - OneMedNet Corp (0001849380) (Subject)

      2/14/24 6:03:43 AM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)

      SC 13G/A - OneMedNet Corp (0001849380) (Subject)

      2/5/24 1:55:23 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Data Knights Acquisition Corp.

      SC 13G - Data Knights Acquisition Corp. (0001849380) (Subject)

      4/11/23 12:00:45 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $DKDCA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OneMedNet Network Expands with New Partnership with Large Academic Research Medical Center to Benefit its Life Science Company Clients

      ~ Partnership To Leverage Real World Data for Life Science Innovation Accelerating New Diagnostic and Treatment Solutions ~MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2023 / OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading curator of regulatory-grade imaging Real World Data ("RWD"), today announced a new partnership with a leading research medical center to accelerate and expand development of new diagnostic and treatment solutions using OneMedNet's iRWD™. Life Science innovators, including pharmaceutical, AI, medical device, and clinical research organizations, are now able to effectively use existing real world data for discovery, development, regulatory-approval, and post-mar

      11/9/23 4:15:00 PM ET
      $DKDCA
      $ONMD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • OneMedNet Completes Business Combination with Data Knights Acquisition Corp. to Become a Publicly Traded Company

      OneMedNet Common Stock to Trade on Nasdaq Under Ticker "ONMD" Tomorrow, Wednesday, November 8, 2023OneMedNet to Fully Embark on its Growth Strategy as it Spearheads the Imaging RWD Solution in the $400 Billion Clinical MarketMINNEAPOLIS, MN / ACCESSWIRE / November 7, 2023 / OneMedNet Corporation (NASDAQ:DKDCA)(NASDAQ:DKDCW) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real World Data ("RWD"), through its proven OneMedNet iRWD™ solution, today announced that it has completed its previously announced business combination with Data Knights Acquisition Corp. ("Data Knights"). The business combination was approved at a special meeting of Data Knights' stockholde

      11/7/23 2:00:00 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Data Knights Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination

      MINNEAPOLIS, MN and LONDON, UK / ACCESSWIRE / October 12, 2023 / Data Knights Acquisition Corp. ("Data Knights" or the "Company") (NASDAQ:DKDCU, DKDCA, DKDCW))), a special purpose acquisition company, today announced that on October 10, 2023 it caused to be deposited $75,000 into the Company's trust account, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from October 11, 2023 to November 11, 2023 (the "Extension"). The Extension is the third of nine (9) one-month extensions permitted under the Company's governing documents. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains statements

      10/12/23 4:45:00 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $DKDCA
    SEC Filings

    See more
    • Data Knights Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - OneMedNet Corp (0001849380) (Filer)

      2/9/24 4:15:31 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-1 filed by Data Knights Acquisition Corp.

      S-1 - OneMedNet Corp (0001849380) (Filer)

      12/18/23 8:29:14 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Data Knights Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OneMedNet Corp (0001849380) (Filer)

      11/22/23 5:30:12 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $DKDCA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Casey Paul claimed ownership of 599,172 shares (SEC Form 3)

      3 - OneMedNet Corp (0001849380) (Issuer)

      11/15/23 4:18:48 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • New insider Kosasa Thomas claimed ownership of 4,952,409 shares (SEC Form 3)

      3 - OneMedNet Corp (0001849380) (Issuer)

      11/15/23 2:08:21 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Owl Creek Asset Management, L.P. disposed of $5,175,450 worth of shares (465,000 units at $11.13)

      4 - Data Knights Acquisition Corp. (0001849380) (Issuer)

      8/21/23 6:18:49 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $DKDCA
    Leadership Updates

    Live Leadership Updates

    See more
    • OneMedNet Appoints Healthcare IT Executive, Aaron Green, as President

      ~ Signaling a New Chapter of Growth for the Innovative Solution of Real World Data~MINNEAPOLIS, MN / ACCESSWIRE / May 23, 2023 / OneMedNet Corporation ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Imaging Real Word Data, through its proven OneMedNet iRWD™ solution, today announced the expansion of its executive team with the appointment of healthcare technology veteran, Aaron Green, as President. In this new role, Green will be responsible for all the major growth functions and lead engagement with existing clients, new clients, sales operations, marketing, communications, and product innovation, reporting directly to the CEO.Green is a healthcare technology busines

      5/23/23 4:05:00 PM ET
      $DKDCA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care